Blood Reviews

Papers
(The TQCC of Blood Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting259
Interplay between platelets and coagulation164
Targeting MCL-1 in hematologic malignancies: Rationale and progress131
Coagulation and anticoagulation in COVID-19125
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system116
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes108
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis98
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents86
The looming storm: Blood and cytokines in COVID-1965
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions64
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved63
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment59
A review of FLT3 inhibitors in acute myeloid leukemia57
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map55
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities54
Role of inflammation in the biology of myeloproliferative neoplasms50
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research49
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions48
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation46
Illness and prognostic understanding in patients with hematologic malignancies42
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities41
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies40
Current state and next-generation CAR-T cells in multiple myeloma40
Current management strategies for polycythemia vera and essential thrombocythemia39
Inherited thrombocytopenias: an updated guide for clinicians38
Discussing investigational AAV gene therapy with hemophilia patients: A guide38
Current and emerging strategies for management of myelodysplastic syndromes35
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer32
Second primary malignancies in multiple myeloma: A review32
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature29
IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly29
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation28
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options27
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies25
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models25
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness25
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma24
CLL update 2022: A continuing evolution in care24
Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management24
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?23
Complement activation in COVID-19 and targeted therapeutic options: A scoping review23
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?22
The emerging role of red blood cells in cytokine signalling and modulating immune cells22
It takes two to thrombosis: Hemolysis and complement22
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag22
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways22
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic22
Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential21
Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations21
Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions21
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers21
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis21
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation21
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?21
Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations21
Immune thrombocytopenia: A review of upfront treatment strategies21
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians21
Artificial intelligence in hematological diagnostics: Game changer or gadget?20
Optimising prophylaxis in haemophilia A: The ups and downs of treatment20
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression20
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity19
Magnesium: The overlooked electrolyte in blood cancers?19
Metabolic regulation of the bone marrow microenvironment in leukemia19
A review on how to do hematology consults during COVID-19 pandemic19
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment18
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option18
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations18
AML and the art of remission maintenance18
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis18
Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics17
Revisiting Richter transformation in the era of novel CLL agents17
The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia17
Germline genetic factors in the pathogenesis of myeloproliferative neoplasms17
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management16
Peripheral neuropathy in hematologic malignancies – Past, present and future16
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation16
Determinants of severity in sickle cell disease16
A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia16
0.025357007980347